Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | F3 | P13726 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | USP7 | Q93009 | 1/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050527 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL15132632 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30222071 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL15883003 | 0.92 | PTPN1 (0.66) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL13559844 | 0.92 | PTPN1 (0.66) | PTPN1ALOX5F3USP2LMNA | |
| Barringtogenol C SCHEMBL1049164 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| Barringtogenol C SCHEMBL15132635 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| Barringtogenol C SCHEMBL14871943 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| SCHEMBL1046309 | 0.90 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30893653 | 0.90 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083753-A1 | Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture | FLORIDA RES GROUP LLC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20240114943-A1 | TASTE-IMPROVING COMPOSITIONS AND USES THEREOF | AMAI PROTEINS LTD. (IL) | 2024-04-11 | — | — | US | disclosed |
| EP-4271701-A1 | TASTE-IMPROVING COMPOSITIONS AND USES THEREOF | Amai Proteins Ltd. (IL) | 2023-11-08 | — | — | EP | disclosed |
| US-11432573-B2 | Food and beverage sweeteners | CAVALERI HEALTH, INC. (CA) | 2022-09-06 | — | — | US | disclosed |
| WO-2022144892-A1 | TASTE-IMPROVING COMPOSITIONS AND USES THEREOF | AMAI PROTEINS LTD. (IL) | 2022-07-07 | — | — | WO | disclosed |
| US-20200229475-A1 | FOOD AND BEVERAGE SWEETENERS | CAVALERI FRANCO (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20200154748-A1 | FOOD AND BEVERAGE SWEETENERS | CAVALERI HEALTH, INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2019018940-A1 | FOOD AND BEVERAGE SWEETENERS | CAVALERI FRANCO (CA) | 2019-01-31 | — | — | WO | disclosed |
| US-20160271199-A1 | Taste Modifiers and Therapeutic Methods Thereof | Weight Sciences, LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20090285919-A1 | Rice Bran Extracts for Inflammation and Methods of Use Thereof | HALPERN, BARUCH | 2009-11-19 | — | — | US | disclosed |
| US-20090155388-A1 | WEIGHT PHYTO-NUTRACEUTICAL SYNERGISTIC COMPOSITION | OLALDE JOSE ANGEL | 2009-06-18 | — | — | US | disclosed |
| US-20080160116-A1 | Compositions and Methods Comprising Zingiber Species | HERBALSCIENCE SINGAPORE PTE. LTD (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008070783-A2 | COMPOSITIONS AND METHODS COMPRISING ZINGIBER SPECIES | HERBALSCIENCE SINGAPORE PTE. LTD. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20020187204-A1 | Diet composition and method of weight management | ALVIAR BARBARA (US) | 2002-12-12 | — | — | US | disclosed |
| US-6413545-B1 | ADMINISTERING MIXTURE CONTAINING PLANT EXTRACTS; APPETITE SUPPRESSANT | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2002-07-02 | — | — | US | disclosed |
| WO-2000012080-A1 | DIET COMPOSITION AND METHOD OF WEIGHT MANAGEMENT | AMWAY CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| EP-0406516-A1 | A process for extracting the concentrated gymnemate from gymnema sylvestre and an equipment for using in the process | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 1991-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080160116-A1 | Compositions and Methods Comprising Zingiber Species | AGL, SQLE, RBPJ | PTPN1 3368/4885ALOX5 28/4885F3 587/4885 |
| US-20260083753-A1 | Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture | SLC2A4, NPC1L1, SLC2A3 | PTPN1 3677/4885ALOX5 217/4885F3 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.